Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) has announced a plan to revise its Articles of Association following two significant developments: the March 2025 update of the China Securities Regulatory Commission’s (CSRC) Guidelines for the Articles of Association of Listed Companies and the company’s Hong Kong Main Board listing completed on 30 March 2026.

The board resolved on 29 April 2026 to propose a package of amendments designed to align the company’s governing document with the latest regulatory requirements and its new capital structure. Key context includes:

• Capital structure shift: DIAGENS-B issued 7.99 million H shares (RMB1.00 nominal value each) in its initial public offering and simultaneously converted all previous unlisted shares into H shares. Post-offering, total share capital stands at 88.88 million H shares.

• Governance alignment: The revisions will incorporate the CSRC’s 2025 guideline updates and add “housekeeping” changes aimed at enhancing corporate governance.

The proposed amendments require approval via special resolution at the forthcoming annual general meeting. A circular detailing the changes will be distributed to shareholders in due course.

As of the announcement date, the board comprises two executive directors (Dr. Song Ning and Mr. Weng Chih-Hsin), three non-executive directors (Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao) and three independent non-executive directors (Mr. Cha Yang, Ms. Zhang Jing and Mr. Wang Kaifeng).